These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24915266)

  • 1. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.
    Lipska KJ; Ross JS; Van Houten HK; Beran D; Yudkin JS; Shah ND
    JAMA; 2014 Jun; 311(22):2331-3. PubMed ID: 24915266
    [No Abstract]   [Full Text] [Related]  

  • 2. Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002-2013.
    Hua X; Carvalho N; Tew M; Huang ES; Herman WH; Clarke P
    JAMA; 2016 Apr; 315(13):1400-2. PubMed ID: 27046369
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of Out-of-Pocket Spending With Insulin Adherence in Medicare Part D.
    Trish E; Kaiser K; Joyce G
    JAMA Netw Open; 2021 Jan; 4(1):e2033988. PubMed ID: 33496792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of diabetes medication adherence and healthcare costs in patients using mail order pharmacy and retail pharmacy.
    Devine S; Vlahiotis A; Sundar H
    J Med Econ; 2010; 13(2):203-11. PubMed ID: 20345227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014-2019.
    Neilson LM; Munshi KD; Peasah SK; Huang Y; Swart ECS; Henderson R; Manolis C; Good CB
    Med Care; 2021 Sep; 59(9):789-794. PubMed ID: 34183622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource utilization with insulin pump therapy for type 2 diabetes mellitus.
    Lynch PM; Riedel AA; Samant N; Fan Y; Peoples T; Levinson J; Lee SW
    Am J Manag Care; 2010; 16(12):892-6. PubMed ID: 21348559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008.
    Shrestha SS; Zhang P; Li R; Thompson TJ; Chapman DP; Barker L
    Diabetes Res Clin Pract; 2013 Apr; 100(1):102-10. PubMed ID: 23490596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Assessment of Glycaemic Control and Modes of Health Financing among Type 2 Diabetic Patients Attending a Teaching Hospital in South-western Nigeria.
    Attoye TE; Adebobola PA; Inem V
    West Afr J Med; 2020; 37(3):237-247. PubMed ID: 32476117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
    Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
    Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
    Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
    Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting insulin analogs versus human insulins.
    Garg SK; Naik RG
    Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
    [No Abstract]   [Full Text] [Related]  

  • 13. Health care costs associated with treatment modification in type 2 diabetes mellitus patients taking oral anti-diabetic drugs.
    Nrishnarajah G; Bhosle M; Chapman R
    Manag Care; 2011 Jun; 20(6):42-8. PubMed ID: 21739924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetes].
    Schröder J; Kerner W
    Dtsch Med Wochenschr; 2009 Nov; 134(46):2355; author reply 2355-6. PubMed ID: 19894207
    [No Abstract]   [Full Text] [Related]  

  • 16. Post-marketing observational trials and catastrophic health expenditure.
    Yudkin JS
    BMJ; 2012 Jun; 344():e3987. PubMed ID: 22692653
    [No Abstract]   [Full Text] [Related]  

  • 17. ["The Lantus case": and yet it does move (or not?)].
    Schöffski O
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
    [No Abstract]   [Full Text] [Related]  

  • 18. [Basal insulin in discussion--clinical and health economics aspects].
    Middeke M
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S99; discussion S124-6. PubMed ID: 18686223
    [No Abstract]   [Full Text] [Related]  

  • 19. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D; Lee WC; Balu S; Joshi AV; Pashos CL
    Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.